Health
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa’s Strategic Focus on Ovarian Cancer and Autoimmune Disease ProgramsCAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Advisory Board to a combined Scientific and Medical Advisory Board as the company advances toward clinical trials in ovarian cancer a
About this update from Ernexa Therapeutics Inc.
[{"type":"image","alt":"Ernexa Therapeutics Inc.","displaySize":"","headline":null,"caption":"Ernexa Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":166,"url":"https://media.zenfs.com/en/globenewswire.com/5060d0692cdc61118022bf7e5069f69d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_oDYUSflXSfeQ8zZ8t_rmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5060d0692cdc61118022bf7e5069f69d","width":300,"height":166}},"lazy":false},{"type":"text","content":"Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa’s Strategic Focus on Ovarian Cancer and Autoimmune Disease Programs","length":133,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Advisory Board to a combined Scientific and Medical Advisory Board as the company advances toward clinical trials in ovarian cancer and autoimmune disease. This evolution marks a significant milestone in Ernexa’s transition from research to clinical-stage development. This comes on the heels of Ernexa’s recently strengthened financial position and is part of a broader strategy to accelerate its lead programs toward the clinic.","length":664,"tagName":"p"},{"type":"text","content":"Joining the advisory board are two distinguished physicians: Amir Anthony Jazaeri, M.D., a leader in gynecologic oncology at The University of Texas MD Anderson Cancer Center, and Anna Helena Jonsson, M.D., Ph.D., an expert in autoimmune disease and immunology at the University of Colorado School of Medicine. Dr. Jazaeri will help guide the company’s ovarian cancer program into the clinic, while Dr. Jonsson will lead translational strategy for Ernexa’s autoimmune pipeline.","length":477,"tagName":"p"},{"type":"text","content":"“As we prepare to advance our programs into clinical development, we’re proud to welcome renowned medical leaders to guide us,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “As we move toward key inflection points in our pipeline, their deep expertise in translational medicine and patient-centered innovation will be instrumental in advancing our lead programs. Our tea...